GMC/RES 25/21 and Its Adoption into Argentine Law

1. Key takeaways

GMC/RES 25/21 is the MERCOSUR-level Technical Regulation on the Registration of Medical Devices, adopted in Montevideo on October 13, 2021; it has itself repealed the older GMC 40/00. It was transposed into Argentine domestic law through Disposición ANMAT 64/2025, with the full text published as an annex to that Disposición in the Official Gazette.

The regulation is built around Annexes I–V: Annex II contains the classification rules (22 rules), Part Three, Article 6 sets the basic document list, Annex IV contains the labeling requirements, and Annex V provides the technical report format. These four locations are the ones a company genuinely needs to compare against word by word, because they determine how the product is argued, documented, labeled and reported.

Everything else in the regulation — definitions, scope, general obligations — is important for orientation, but the operative work of preparing a dossier happens at those four anchors. A team that masters Annex II, Part Three Article 6, Annex IV and Annex V has effectively mastered the Argentine registration dossier.

2. Legal basis

The instruments below cover the regional technical regulation itself, the domestic instrument that gives it force in Argentina, the foundational essential-requirements resolution, and the treaty obligation that makes transposition mandatory.

3. Expert insights

Insight one: GMC 25/21 is a resolution, not a recommendation, and member states are under a binding obligation to transpose it. This determines that it is not an international guideline that may optionally be adopted, but regional legislation that must be implemented in full through domestic law. Argentina therefore cannot partially adopt it or defer its application; ANMAT could only incorporate it in complete form through a single Disposición. For companies, this means the content can be treated as fixed — there is no national deviation to wait for or negotiate around.

Insight two: the synchronized entry-into-force mechanism creates a special status — transposed but not yet formally in force at regional level. Argentina has completed its domestic transposition, and ANMAT’s current published position is applied under 64/2025; however, the unified entry into force of GMC 25/21 still awaits completion of transposition by all member states. This coexistence of factual application and legal effectiveness requires companies to prepare under the new regulation while remaining sensitive to any transitional arrangements that the regional process may still produce.

Insight three: GMC 25/21 converges closely with the EU MDR on definitions and classification logic. The definition of a medical device covers software, and classification is rule-driven rather than list-driven. Companies holding CE technical documentation can reuse their classification justifications, risk management reports and clinical evaluation material to a large extent, and the conversion cost is significantly lower than building from zero. The remaining work is mapping, not rewriting — provided the mapping is done honestly and documented.

4. Practical recommendations

1. Build a cross-reference table annex by annex. Map Annex II of GMC 25/21 (classification), Part Three Article 6 (documents), Annex IV (labeling) and Annex V (technical report) item by item against the company’s existing documentation, and mark every gap explicitly.
2. Keep a difference-explanation page when reusing CE/MDR material. Whenever an EU document is cited, add one page explaining the applicability judgment of that material under the Argentine rules, so reviewers can locate the reasoning quickly instead of guessing.
3. Use the essential requirements of GMC 72/98 as the skeleton of the technical report. Annex V requires safety and effectiveness to be described against the essential requirements of GMC 72/98; this is the item most frequently missed by companies from China.
4. Create a regional regulation monitoring role. The entry-into-force notifications of the MERCOSUR secretariat and the transposition progress of each member state should be reviewed quarterly by a designated person, with the findings recorded in the compliance calendar.

5. Verification checklist

• □ Confirmed that GMC/RES 25/21 was adopted on October 13, 2021
• □ Confirmed that it replaced GMC 40/00 and was transposed through Disposición 64/2025
• □ Obtained the full text of Annexes I–V of GMC 25/21 and built the internal cross-reference table
• □ The 22 classification rules of Annex II have been applied to the product classification justification
• □ The five categories of basic documents under Part Three, Article 6 have been addressed item by item
• □ The labeling elements of Annex IV and the technical report format of Annex V have replaced the old templates
• □ A responsible person for regional regulation monitoring has been designated

Regulatory information verified as of October 29, 2026.

In Argentina, GRZAN operates a wholly owned subsidiary that can act as the registration holder and importer for foreign manufacturers, directly undertaking classification determination, pathway selection, GMP and CFS documentation chains, Spanish-language localization of technical documentation and labels, HELENA submissions and deficiency responses, as well as BONITA import notifications, operation of the ARGOS vigilance system, change maintenance and 5-year renewal planning.

The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience and continuously tracks the developments of regulatory authorities worldwide; all published content follows the editorial standard of conclusions first, traceable bases and verifiable figures. For a tailored market access plan for Argentina or the MERCOSUR region covering a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.